Posted by AGORACOM-JC
at 8:42 AM on Wednesday, January 20th, 2021
Company launches first-ever COVID-safe location-based (LBE) Virtual Reality attractions division “UNCONTAINED” to disrupt the marketplace and fulfill demand from its Family Entertainment Center (FEC) clients.
Immersive Tech is planning for a public listing in the first half of 2021.
Leading immersive experience company builds upon current and past relationships with major companies.
Announcement brings creation of the world’s first-ever free-roam interactive VR franchise attraction available for rapid sale to the global attraction and entertainment marketplace.
VANCOUVER, British Columbia, Jan. 20, 2021 — Victory Square Technologies Inc. (“VST”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) , a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that its portfolio company Immersive Tech (“Company”) has launched a premiere new Location-Based Entertainment (LBE) VR attractions division named UNCONTAINED to capitalize on the growing demand for COVID-safe attractions. UNCONTAINED will be the world’s first free-roam interactive VR franchise attraction, built for a COVID world within shipping containers. The experience will allow for up to six players to roam freely within the container while interacting inside a digital environment as a team while making decisions that help guide and define the story.
Immersive Tech designs, engineers and builds custom technology-driven experiences, whether they facilitate brand integration or are aiming to create the best real life adventure possible. The Company recently announced the creation of three unique entertainment escape rooms custom designed and built for Apex Entertainment’s new location in Virginia Beach VA, USA. The three custom room themes include an underwater submarine adventure, a post-war bunker experience, and an AI-controlled warship gone rogue featuring a race against time and a family-friendly focus.
“UNCONTAINED” leverages the manner of design experience that Immersive Tech has gained and honed over the past four years in creating and launching highly successful interactive escape rooms for Family Entertainment Centers. This is complemented by a fundamental understanding of shipping containers as highlighted in their recent 3-room escape experience for Leaps by Bayer, a Bayer Pharmaceutical company, in 2020.
Tags: small cap, small cap stocks, stocks, telehealth, telemedicine, tsx Posted in Victory Square Technologies Inc. | Comments Off on Victory Square Technologies $VST.ca $VSQTF Portfolio Company, Immersive Tech, Announces the Creation of World’s First #COVID-safe Location-Based Entertainment (LBE) Virtual Reality #VR Division “UNCONTAINED” $DBO.ca $YDX.ca $SEV.ca $NTAR.ca
Posted by AGORACOM-JC
at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight.
Saviuk agreed and gave the following reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease. What does this mean?
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
Hesperidin may help against Covid-19 viral replication
Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.
Now you have it. That’s the Valeo story as it applies to just 2 of their amazing products. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
Posted by AGORACOM-JC
at 9:19 AM on Tuesday, January 19th, 2021
Hydreight provides a completely compliant turnkey business model for health professionals to offer fully licensed medical, health & wellness services through an on-demand and on-site platform.
In addition to providing telehealth services, Hydreight also provides a diverse suite of health & wellness protocols that include IV drip, Botox, COVID-19 testing, and other medical and medispa treatments.
Hydreight is a USA certified e-script and telemedicine provider, allowing Hydreight to offer a wide array of health and medical services in all 50 states.
Hydreight provides full pharmaceutical offerings across the United States (Hydreight has full 503B Pharmaceutical supply capabilities ).
Hydreight has established key relationships and supply network chains with major vendors including: Medline, Mckesson, Allergan (Botox), Galderma and numerous pharmacies.
VANCOUVER, British Columbia, Jan. 19, 2021 — Victory Square Technologies Inc. (” Victory Square ” or the “ Company ”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that it has signed a binding letter of intent (the “ LOI ”) dated January 13, 2021 in respect of the acquisition (the “ Acquisition ”) of all of the shares of IV Hydreight Inc. (“ Hydreight ”), a mobile health and wellness service provider operating in the United States.
Founded in 2018, Hydreight provides a unique, custom built, proprietary telemedicine service that allows users to book confidential health & wellness and/or medical services at their home, hotel, office or wherever they may need discreet assistance. The business model of Hydreight leverages decentralized healthcare to bring quality telehealth, medical, health and wellness services to the masses in an efficient, scalable and cost effective way.
Posted by AGORACOM-JC
at 9:09 AM on Tuesday, January 19th, 2021
Announces Appointment of Dr. Jinyu Mo as Senior Vice President, Asia
Opened a product design and development center in Shenzhen, China, which will be focused on the optical engine, reference designs for customer applications and new product activities.
POET also announced the appointment of Dr. Jinyu Mo as its Senior Vice President of Asia, with responsibility for managing the Company’s activities in China and Singapore. Dr. Mo is a highly experienced technical and business veteran of the photonics and optoelectronics industries.
TORONTO, Jan. 19, 2021 — POET Technologies Inc. (“ POET ” or the “ Company ”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced today that it has opened a product design and development center in Shenzhen, China, which will be focused on the optical engine, reference designs for customer applications and new product activities.
POET also announced the appointment of Dr. Jinyu Mo as its Senior Vice President of Asia, with responsibility for managing the Company’s activities in China and Singapore. Dr. Mo is a highly experienced technical and business veteran of the photonics and optoelectronics industries. She has over 22 years of experience spanning several companies, including MACOM Technology Solutions, Bookham/Oclaro, Huawei, I2R in Singapore and Nexvave Photonics Technology Co., which she founded and served as Chief Technology Officer. Dr. Mo was most recently with MACOM as the Senior Director and Chief Scientist of the Lightwave business unit in Asia and site leader in Shenzhen. Dr. Mo received her PhD degree in Optical Communications from Nanyang Technological University (NTU) Singapore. She is a Senior member of IEEE and has been a member of IEEE’s Technical Committees for several international conferences.
POET Optoelectronics Shenzhen Co. Ltd., a wholly foreign-owned enterprise (WFOE) and wholly-owned subsidiary of POET, will augment the Company’s existing design, development and engineering operations in Allentown, Pennsylvania and Singapore. The Shenzhen operation will also support the activities of Super Photonics Xiamen Co. Ltd., the Company’s joint venture with Sanan IC, a subsidiary of Sanan Optoelectronics Co., Ltd. (Shanghai Stock Exchange, SSE: 600703).
Posted by AGORACOM-JC
at 8:11 AM on Tuesday, January 19th, 2021
Access to up to 2,000 US Colleges and Universities with reach of up to 1.5 Million Students
Entered into an agreement to partner with US based, The Campus Agency to create innovative engagement programs for Liquid Avatar to reach the US college and university student, alumni and family market.
KABN NA and The Campus Agency will be working together to engage micro-influencers, develop and launch innovative engagement and Augmented Reality programs to introduce the college and university market to the Liquid Avatar and KABN value programs.
The partnership goals are to increase brand awareness, maximize engagement, educate users on the value proposition of Self Sovereign Identity, and generate user benefits and revenue for the partnership program.
TORONTO, ON / January 19, 2021/KABN Systems NA Holdings Corp. (CSE:KABN)(OTC PINK:TRWRF)(FRA:4T51) (the “Company“, “KABN North America” or “KABN NA“), a North American Fintech solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign Identity (“SSI”) through its Liquid Avatar platform, announces today that it has entered into an agreement to partner with US based, The Campus Agency to create innovative engagement programs for Liquid Avatar to reach the US college and university student, alumni and family market.
KABN NA and The Campus Agency will be working together to engage micro-influencers, develop and launch innovative engagement and Augmented Reality programs to introduce the college and university market to the Liquid Avatar and KABN value programs. The partnership goals are to increase brand awareness, maximize engagement, educate users on the value proposition of Self Sovereign Identity, and generate user benefits and revenue for the partnership program.
With reach to over 2,000 US College and University campuses and over 1.5 Million Gen Z students, alumni and families, The Campus Agency has been supporting innovative direct to student and online marketing programs for over 40 years.
“We’re excited to bring our 40 years of creating success on campus and digital initiatives to Liquid Avatar and to bring this important and innovative program to our collegiate communities, allowing users to manage and control their digital identity and future credentials safely and securely,” said Chris Nyland, Chief Operating Officer, The Campus Agency. “This is our second program with KABN North America and Liquid Avatar, as we’re already jointly a part of the COVID-19 consortium for creating Verifiable Identity Healthcare Credential.”
Posted by AGORACOM-JC
at 9:25 AM on Monday, January 18th, 2021
Announced today that the CEO of the Company, Cameron Chell, will be featured on “Making Money with Charles Payne” on Fox Business.
Segment on Fox Business will focus on Draganfly’s recent announcements in relation to Draganfly’s Varigard spraying program which provides 24-hour sequestration and kill efficacy against pathogens including COVID-19 in a single application.
Los Angeles, CA, Jan. 18, 2021 —Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“ Draganfly ” or the “ Company ”), an award-winning, industry-leading manufacturer and systems developer, announced today that the CEO of the Company, Cameron Chell, will be featured on “Making Money with Charles Payne” on Fox Business.
The segment on Fox Business will focus on Draganfly’s recent announcements in relation to Draganfly’s Varigard spraying program which provides 24-hour sequestration and kill efficacy against pathogens including COVID-19 in a single application.
“I am super excited to share our story with Charles Payne on Fox Business,” said Cameron Chell, CEO Draganfly. “The surface disinfecting market size is surging and expected to reach $1.5 billion by 2027, due in part to the requirement to disinfect large areas like stadiums. Varigard ™ has already established a technical leadership position and we look forward to providing the most advanced drones and services to their customers.”
Cameron Chell’s segment on Fox Business with Charles Payne will air at 2PM ET on Monday, January 18.
Posted by AGORACOM-JC
at 7:14 AM on Monday, January 18th, 2021
Frederic Fasano named President and COO
Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors
MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk, CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”
Posted by AGORACOM-JC
at 4:15 PM on Thursday, January 14th, 2021
Announced the successful completion of a large-scale production of exosomes
Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
This achievement is expected to pave the way for larger tests and studies.
Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.
“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.
Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.
Posted by AGORACOM-JC
at 12:14 PM on Thursday, January 14th, 2021
Commercial launch to impact first half 2021 revenue
$30 million forecasted annual peak sales
8 years of proven in-market safety Internationally
Low molecular weight heparin increasingly used to prevent COVID-19 driven complications
“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.
